Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Pat Roche Elected to The EMCOR Group, Inc. Board of Directors
08:00am, Wednesday, 29'th Oct 2025
NORWALK, Conn.--(BUSINESS WIRE)--EMCOR Group, Inc. (the “Company”) (NYSE: EME) announced today the election of Pat Roche to the Company's Board of Directors, effective October 27, 2025. Mr. Roche,
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
02:00am, Wednesday, 29'th Oct 2025
Basel, 29 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark for its Elecsys® Dengue Ag test – a high-throughput, fully automated immunoassay to be used
Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
02:00am, Tuesday, 28'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the P
Roche Holding AG (RHHBY) Q3 2025 Sales Call Transcript
06:47pm, Thursday, 23'rd Oct 2025
Roche Holding AG (OTCQX:RHHBY) Q3 2025 Sales Call October 23, 2025 8:00 AM EDT Company Participants Thomas Schinecker - Group Chief Executive Officer Alan Hippe - Chief Financial Officer Teresa Graham
RHHBY's Sales Up 7% in First 9 Months of 2025, '25 Earnings View Raised
10:06am, Thursday, 23'rd Oct 2025
Roche's Q3 sales climbed 6% to CHF 14.9B, powered by surging demand for Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus.
Roche Raises Full-Year Earnings Outlook
01:45am, Thursday, 23'rd Oct 2025
The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.
Changes to the Roche Enlarged Corporate Executive Committee
01:30am, Thursday, 23'rd Oct 2025
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-Hautzinger (1975) has been appointed Head of Group Communications and a member of the enlarged Corporate Ex
Roche raises guidance on forecast-beating nine-month sales
01:08am, Thursday, 23'rd Oct 2025
Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected.
Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript
04:44pm, Tuesday, 21'st Oct 2025
Roche Holding AG (OTCQX:RHHBY) Shareholder/Analyst Call October 21, 2025 11:00 AM EDT Company Participants Bruno Eschli - Head of Investor Relations Nilesh Mehta - Global Franchise Head - Ophthalmolog
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
10:36am, Tuesday, 21'st Oct 2025
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
My Top 3 Pharma Stocks
11:38am, Monday, 20'th Oct 2025
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and o
Roche's Gazyva Gets FDA Approval for Lupus Nephritis
02:40am, Monday, 20'th Oct 2025
The Food and Drug Administration approved Gazyva for the treatment of adults receiving standard therapy for a form of lupus that targets the kidneys.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III IMvigor011 study evaluating Tecen
Roche's Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
01:05am, Monday, 20'th Oct 2025
Basel, 20 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for peop
FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis
01:00am, Monday, 20'th Oct 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Gazyva�
